Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as monotherapy or in combination with oral glucose-lowering drugs ± insulin. The six subcutaneous GLP-1RA formulations (i.e. twice-daily exenatide, once-daily liraglutide and lixisenatide, and once-weekly dulaglutide, exenatide and semaglutide) currently available in the EU and USA have many similarities, but also some unique features and properties. By stimulating GLP-1 receptors, GLP-1RAs increase insulin secretion and suppress glucagon release in a glucose-dependent manner, thereby improving clinical and patient-reported outcomes related to glycaemic control and weight. They also have been shown to reduce, or at least not increase, the risk of major cardiovascular outcomes. GLP-1RAs are generally well tolerated, with gastrointestinal and injection-site reactions being the most troublesome drug-related adverse events, and are associated with a very low intrinsic risk of hypoglycaemia. Treatment with GLP-1RAs should be customized to meet the clinical needs and personal preferences of the individual.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 3×
“The primary MACE component appearing to be driving the reduction in MACE was CV death with liraglutide [43], and non-fatal stroke with dulaglutide [44] and semaglutide [45], with no other significant differences in the risk of individual MACE components shown between individual GLP-1RAs and placebo (Table 4).”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“The primary MACE component appearing to be driving the reduction in MACE was CV death with liraglutide [43], and non-fatal stroke with dulaglutide [44] and semaglutide [45], with no other significant differences in the risk of individual MACE components shown between individual GLP-1RAs and placebo (Table 4).”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
TOXIC-SHOCK SYNDROME NOT ASSOCIATED WITH MENSTRUATION
Reingold, A., Shands, K., Dan, B., & Broome, C. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92552-1 · Cited by 1,164
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 6×
“27 mmol/L) [60] Immunogenicity and allergic reactions Potential for antibody production is greater with GLP-1RAs whose structure is based on exendin-4, as they are less homologous to human GLP-1 than those based on human GLP-1 (Table 1) [19, 49] Incidence of antibody formation: ≈ 45% of exenatide IR and ER, 70% of lix…”
BackgroundInfluentialPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495 · cited 2×
“General health-related quality-of-life (HR-QoL) was evaluated in several RCTs, with once-weekly GLP-1RAs showing consistent and significant improvements from baseline for most HR-QoL-related PROs, such as EuroQol 5 Dimension, Psychological General Well-Being Index and Short-Form-36 (SF-36) total and/or domain scores […”
BackgroundMethodDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464 · cited 2×
“General health-related quality-of-life (HR-QoL) was evaluated in several RCTs, with once-weekly GLP-1RAs showing consistent and significant improvements from baseline for most HR-QoL-related PROs, such as EuroQol 5 Dimension, Psychological General Well-Being Index and Short-Form-36 (SF-36) total and/or domain scores […”
BackgroundMethodHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416 · cited 3×
“Overall, the long-acting GLP1RAs (once-weekly dulaglutide, liraglutide and exenatide ER) were superior to the short-acting agents (twice-daily exenatide and lixisenatide) with regard to improvements in glycaemic control, whereas no differences were shown in comparisons between either the various short-acting drugs or…”
BackgroundInfluentialSemaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318 · cited 1×
“Microvascular effects Diabetic retinopathy: ↑ risk of early worsening with semaglutide (consistent with early worsening that occurs with insulin; associated with rapid and sizeable improvements in glycaemic control) [57], but not other GLP-1RAs [58, 59] Nephropathy: ↓ risk [58, 59] Lipid levels Exenatide IR/ER, liragl…”
BackgroundReview of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265 · cited 1×
“However, the long-acting GLP-1RAs offer the pharmacological advantage of reducing plasma glucose levels across the 1-day or 1-week administration intervals [18, 20, 22].”
BackgroundNew IDF clinical practice recommendations for managing type 2 diabetes in primary care
Aschner, P. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.002 · Cited by 264
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
Su, B., Sheng, H., Zhang, M., Bu, L., Yang, P., Li, L., Li, F., Sheng, C., Han, Y., Qu, S., et al. (2015) · Endocrine · doi:10.1007/s12020-014-0361-4 · Cited by 203 · cited 1×
“↑ risk of bone fractures: linked to exenatide but not liraglutide [64]; causality is controversial [49]”
BackgroundA multicenter observational study of incretin-based drugs and heart failure
Filion, K. B., Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506115 · Cited by 196
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Spain, C. V., Wright, J. J., Hahn, R. M., Wivel, A., & Martin, A. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.05.009 · Cited by 117
Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12902 · Cited by 111
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Best, J. H., Boye, K. S., Rubin, R. R., Cao, D., Kim, T. H., & Peyrot, M. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02752.x · Cited by 97
Kostev, K., Ouwens, M., Grandy, S., Johnsson, K. M., & Qiao, Q. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s99732 · Cited by 92
Dicembrini, I., Nreu, B., Scatena, A., Andreozzi, F., Sesti, G., Mannucci, E., & Monami, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1031-9 · Cited by 92
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
Monami, M., Nreu, B., Scatena, A., Giannini, S., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0698-7 · Cited by 74
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
Johnston, S. S., Nguyen, H. P., Felber, E., Cappell, K. A., Nelson, J. K., Chu, B. C., & Kalsekar, I. D. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0166-0 · Cited by 71
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
Mirabelli, M., CHIEFARI, E. D., Puccio, L., FOTI, D. P., & Brunetti, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103664 · Cited by 69
Giorgino, F., Penfornis, A., Pechtner, V., Gentilella, R., & Corcos, A. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s151736 · Cited by 68
Sun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L., & Zhan, S. (2012) · Experimental Diabetes Research · doi:10.1155/2012/230624 · Cited by 58 · cited 2×
“Short-acting GLP-1RAsb: ↑ risk due to substantial delays in gastric emptying; ↓ slowly over several months; may lead to treatment discontinuation (long-acting GLP-1RAs do not delay gastric emptying; nausea rapidly resolves) [19, 49, 52]”
BackgroundBest, J. H., Rubin, R. R., Peyrot, M., Li, Y., Yan, P., Malloy, J., & Garrison, L. P. (2011) · Diabetes Care · doi:10.2337/dc10-1119 · Cited by 57
Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J. W., Kang, S., Joh, H.-K., Kwon, H., Kim, J., & Park, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177646 · Cited by 53
Nguyen, H., Dufour, R., & Caldwell-Tarr, A. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0470-y · Cited by 52
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0825-1 · Cited by 52
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Ahrén, B. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12911 · Cited by 48
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
Kayaniyil, S., Lozano-Ortega, G., Bennett, H. A., Johnsson, K., Shaunik, A., Grandy, S., & Kartman, B. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0155-1 · Cited by 43 · cited 1×
“A meta-analysis found no significant differences in the rates of nausea and discontinuation for ADRs between exenatide ER and dulaglutide, exenatide IR, liraglutide and lixisenatide as add-ons to metformin [66].”
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 39
The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy
Pang, B., Zhou, H., & Kuang, H. (2017) · Peptides · doi:10.1016/j.peptides.2017.08.003 · Cited by 36 · cited 1×
“Microvascular effects Diabetic retinopathy: ↑ risk of early worsening with semaglutide (consistent with early worsening that occurs with insulin; associated with rapid and sizeable improvements in glycaemic control) [57], but not other GLP-1RAs [58, 59] Nephropathy: ↓ risk [58, 59] Lipid levels Exenatide IR/ER, liragl…”
BackgroundYu, M., Brunt, K. V., Varnado, O. J., & Boye, K. S. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12624 · Cited by 31
Li, Y., & Rosenblit, P. D. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1051-2 · Cited by 31
Unni, S., Wittbrodt, E., Ma, J., Schauerhamer, M., Hurd, J., Ruiz‐Negrón, N., & McAdam‐Marx, C. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13107 · Cited by 29
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Madsbad, S. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.11.003 · Cited by 19
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
Heile, M., Wyne, K., Billings, L., Cannon, A., Handelsman, Y., & Shannon, M. H. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s42 · Cited by 14 · cited 1×
“As patients with T2D have an increased risk of adverse cardiovascular (CV) outcomes, current management of T2D includes the reduction of CV risk factors including, but not limited to, hyperglycaemia [39, 40].”
Handelsman, Y., Wyne, K., Cannon, A., Shannon, M., & Schneider, D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s14 · Cited by 14 · cited 2×
“Although many ADRs appear to be class effects, the tolerability profiles of individual GLP-1RAs are affected by differences in their structure and duration of effect with regard to some ADRs, especially with regard to gastrointestinal ADRs and injection-site reactions (Table 5) [19, 49, 50].”
BackgroundHuang, Y., Li, J., Chen, S., Zhao, S., Huang, J., Zhou, J., & Xu, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.922210 · Cited by 13
Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL
Torekov, S. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy124 · Cited by 10
Uusinarkaus, K., Rodbard, H. W., Gaal, L. V., Wilding, J. P. H., Hansen, T. M., Sandberg, A., Tadayon, S., & Davies, M. J. (2019) · Diabetes · doi:10.2337/db19-1020-p · Cited by 1
Cited by
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
“The safety of semaglutide was consistent with that reported in the phase 2 study with oncedaily dosing in participants with obesity(14) and in the trials of once-weekly subcutaneous semaglutide in persons with type 2 diabetes (involving more than 8000 participants receiving doses up to 1 mg),(12) as well as with that…”
ResultOnce-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730
Wang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Singh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
Metadata
- Authors
- Lyseng-Williamson, K. A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Lyseng-Williamson, Katherine A.
- Venue
- Clinical Drug Investigation
- Published
- 2019-07-18
- Volume
- 39
- Issue
- 8
- Pages
- 805-819
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- PMC
- PMC6746674
- OpenAlex
- W2963614034
- Cited by
- 87
- References
- 65
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 11 · 2023: 8 · 2022: 9 · 2021: 18 · 2020: 12
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Clinical Drug Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, insulin secretion, glucagon suppression, glycemic control, weight loss, cardiovascular outcomes, gastrointestinal adverse effects, hypoglycemia risk, personalized treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.